Alnylam Pharmaceuticals Inc.

147.50+1.20+0.82%Vol 1.53M1Y Perf -15.76%
Jun 24th, 2022 16:00 DELAYED
BID146.20 ASK147.78
Open147.68 Previous Close146.30
Pre-Market- After-Market146.81
 - -  -0.69 -0.47%
Target Price
212.33 
Analyst Rating
Strong Buy 1.50
Potential %
43.95 
Finscreener Ranking
     41.67
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
     38.51
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
     37.70
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
31.69 
Earnings Rating
Buy
Market Cap17.82B 
Earnings Date
2nd Aug 2022
Alpha0.01 Standard Deviation0.13
Beta0.94 

Today's Price Range

144.34148.25

52W Range

117.58212.00

5 Year PE Ratio Range

-16.60-16.60

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
7.59%
1 Month
16.37%
3 Months
-9.96%
6 Months
-24.11%
1 Year
-15.76%
3 Years
107.34%
5 Years
73.10%
10 Years
1 167.18%

TickerPriceChg.Chg.%
ALNY147.501.20000.82
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
4.00
4.30
0.70
2.48
-4.80
Leverage Ratio 5.40
ProfitabilityValueIndustryS&P 500US Markets
83.60
-84.00
-74.20
-447.70
-97.99
RevenueValueIndustryS&P 500US Markets
879.98M
7.28
96.76
73.44
Earnings HistoryEstimateReportedSurprise %
Q01 2022-1.93-2.00-3.63
Q04 2021-1.47-2.16-46.94
Q03 2021-1.51-1.72-13.91
Q02 2021-1.57-1.61-2.55
Q01 2021-1.75-1.712.29
Q04 2020-1.93-2.09-8.29
Q03 2020-1.75-2.18-24.57
Q02 2020-1.82-1.5614.29
Earnings Per EndEstimateRevision %Trend
6/2022 QR-1.631.21Positive
9/2022 QR-1.74-9.43Negative
12/2022 FY-7.07-5.68Negative
12/2023 FY-3.233.87Positive
Next Report Date2nd Aug 2022
Estimated EPS Next Report-1.63
Estimates Count9
EPS Growth Next 5 Years %-
Volume Overview
Volume1.53M
Shares Outstanding120.81K
Shares Float102.53M
Trades Count19.51K
Dollar Volume224.76M
Avg. Volume875.11K
Avg. Weekly Volume996.28K
Avg. Monthly Volume820.17K
Avg. Quarterly Volume808.89K

Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) stock closed at 147.5 per share at the end of the most recent trading day (a 0.82% change compared to the prior day closing price) with a volume of 1.53M shares and market capitalization of 17.82B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 1453 people. Alnylam Pharmaceuticals Inc. CEO is John M. Maraganore.

The one-year performance of Alnylam Pharmaceuticals Inc. stock is -15.76%, while year-to-date (YTD) performance is -13.02%. ALNY stock has a five-year performance of 73.1%. Its 52-week range is between 117.58 and 212, which gives ALNY stock a 52-week price range ratio of 31.69%

Alnylam Pharmaceuticals Inc. currently has a PE ratio of -18.30, a price-to-book (PB) ratio of 41.29, a price-to-sale (PS) ratio of 18.82, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -26.70%, a ROC of -56.48% and a ROE of -134.53%. The company’s profit margin is -97.99%, its EBITDA margin is -74.20%, and its revenue ttm is $879.98 Million , which makes it $7.28 revenue per share.

Of the last four earnings reports from Alnylam Pharmaceuticals Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-1.63 for the next earnings report. Alnylam Pharmaceuticals Inc.’s next earnings report date is 02nd Aug 2022.

The consensus rating of Wall Street analysts for Alnylam Pharmaceuticals Inc. is Strong Buy (1.5), with a target price of $212.33, which is +43.95% compared to the current price. The earnings rating for Alnylam Pharmaceuticals Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Alnylam Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Alnylam Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 14.27, ATR14 : 6.06, CCI20 : 176.23, Chaikin Money Flow : 0.26, MACD : 2.27, Money Flow Index : 73.47, ROC : 10.07, RSI : 64.47, STOCH (14,3) : 97.08, STOCH RSI : 1.00, UO : 71.92, Williams %R : -2.92), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Alnylam Pharmaceuticals Inc. in the last 12-months were: Akshay K. Vaishnaw (Option Excercise at a value of $682 542), Akshay K. Vaishnaw (Sold 13 423 shares of value $2 661 443 ), John M. Maraganore (Option Excercise at a value of $882 324), John M. Maraganore (Sold 67 957 shares of value $12 615 995 ), Laurie B. Keating (Option Excercise at a value of $1 488 270), Laurie B. Keating (Sold 16 812 shares of value $3 108 598 ), Steven M. Paul (Option Excercise at a value of $169 950), Steven M. Paul (Sold 15 000 shares of value $2 560 371 ), Tolga Tanguler (Option Excercise at a value of $0), Yvonne Greenstreet (Option Excercise at a value of $4 091 234), Yvonne Greenstreet (Sold 53 064 shares of value $10 559 736 ), Yvonne L Greenstreet (Option Excercise at a value of $4 091 234), Yvonne L Greenstreet (Sold 53 064 shares of value $10 559 736 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
11 (68.75 %)
10 (66.67 %)
11 (68.75 %)
Moderate Buy
2 (12.50 %)
2 (13.33 %)
3 (18.75 %)
Hold
3 (18.75 %)
3 (20.00 %)
2 (12.50 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.50
Strong Buy
1.53
Strong Buy
1.41

Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals Inc is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. In addition to FDA-approved patisiran (Onpattro) for amyloidosis and givosiran (Givlaari) for acute hepatic porphyria, Alnylam has several partnered several pipeline candidates in rare genetic diseases, liver diseases, and other indications as well. Up-front fees from research partnerships with firms such as Regeneron, Sanofi, and The Medicines Company have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

CEO: John M. Maraganore

Telephone: +1 617 551-8200

Address: 675 West Kendall Street, Cambridge 02142, MA, US

Number of employees: 1 453

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

62%38%

Bearish Bullish

65%35%

Bearish Bullish

61%39%

TipRanks News for ALNY

Thu, 23 Jun 2022 10:45 GMT Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Zynerba Pharmaceuticals (ZYNE)

- TipRanks. All rights reserved.

Wed, 15 Jun 2022 12:25 GMT Analysts Are Bullish on Top Healthcare Stocks: Alnylam Pharma (ALNY), Amgen (AMGN)

- TipRanks. All rights reserved.

Wed, 15 Jun 2022 10:15 GMT Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Tenaya Therapeutics (TNYA)

- TipRanks. All rights reserved.

Tue, 24 May 2022 12:26 GMT Analysts Are Bullish on These Healthcare Stocks: Alnylam Pharma (ALNY), Cytokinetics (CYTK)

- TipRanks. All rights reserved.

Tue, 10 May 2022 10:35 GMT Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Geron (GERN) and Arcturus Therapeutics (ARCT)

- TipRanks. All rights reserved.

Sat, 30 Apr 2022 01:45 GMT Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Gilead Sciences (GILD) and Stryker (SYK)

- TipRanks. All rights reserved.

Sat, 30 Apr 2022 01:15 GMT Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Eli Lilly & Co (LLY) and Humana (HUM)

- TipRanks. All rights reserved.

Fri, 29 Apr 2022 16:35 GMT Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Baxter International (BAX) and Merck & Company (MRK)

- TipRanks. All rights reserved.

Fri, 29 Apr 2022 12:40 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: Alnylam Pharma (ALNY), Baxter International (BAX) and Community Health (CYH)

- TipRanks. All rights reserved.

Fri, 29 Apr 2022 11:15 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: Alnylam Pharma (ALNY) and Sanofi (OtherSNYNF)

- TipRanks. All rights reserved.

Tue, 12 Apr 2022 10:12 GMT Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Actinium Pharmaceuticals (ATNM) and Bicycle Therapeutics (BCYC)

- TipRanks. All rights reserved.

Wed, 06 Apr 2022 01:55 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY), Biogen (BIIB) and Pacira Pharmaceuticals (PCRX)

- TipRanks. All rights reserved.

Mon, 04 Apr 2022 15:55 GMT Alnylam Pharma (ALNY) Gets a Buy Rating from Needham

- TipRanks. All rights reserved.

Sun, 13 Feb 2022 14:46 GMT Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), AstraZeneca (AZN) and Dexcom (DXCM)

- TipRanks. All rights reserved.

Fri, 11 Feb 2022 12:25 GMT Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Cigna (CI) and SCYNEXIS (SCYX)

- TipRanks. All rights reserved.

Thu, 10 Feb 2022 18:55 GMT Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Biogen (BIIB)

- TipRanks. All rights reserved.

Fri, 28 Jan 2022 12:25 GMT Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Stryker (SYK) and HCA Healthcare (HCA)

- TipRanks. All rights reserved.

Mon, 24 Jan 2022 13:45 GMT Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), BridgeBio Pharma (BBIO) and Kinnate Biopharma (KNTE)

- TipRanks. All rights reserved.

Mon, 24 Jan 2022 13:25 GMT Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Merck & Company (MRK)

- TipRanks. All rights reserved.

Mon, 24 Jan 2022 11:15 GMT Analysts Are Bullish on Top Healthcare Stocks: Alnylam Pharma (ALNY), Reviva Pharmaceuticals Holdings (RVPH)

- TipRanks. All rights reserved.

Tue, 11 Jan 2022 14:46 GMT Alnylam Pharma (ALNY) Gets a Hold Rating from BMO Capital

- TipRanks. All rights reserved.

Thu, 06 Jan 2022 16:25 GMT Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Biogen (BIIB) and Pacira Pharmaceuticals (PCRX)

- TipRanks. All rights reserved.

News

Stocktwits